Response of a metastatic breast carcinoma with a previously uncharacterized ERBB2 G776V mutation to human epidermal growth factor receptor 2-targeted therapy

Yakov Chudnovsky, Runjun D. Kumar, Alexa B. Schrock, Caitlin Connelly, Kyle Gowen, Garrett M. Frampton, Rachel L. Erlich, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Ron Bose

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalJCO Precision Oncology
Volume2017
Issue number1
DOIs
StatePublished - Jan 1 2017

Cite this

Chudnovsky, Y., Kumar, R. D., Schrock, A. B., Connelly, C., Gowen, K., Frampton, G. M., Erlich, R. L., Stephens, P. J., Miller, V. A., Ross, J. S., Ali, S. M., & Bose, R. (2017). Response of a metastatic breast carcinoma with a previously uncharacterized ERBB2 G776V mutation to human epidermal growth factor receptor 2-targeted therapy. JCO Precision Oncology, 2017(1), 1-9. https://doi.org/10.1200/PO.16.00037